We provide you with 20 years of free, institutional-grade data for EQ stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of EQ. Explore the full financial landscape of EQ stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-14 | 0001746466 | EQ | 10-Q | Url |
| 2025-05-14 | 0001746466 | EQ | 10-Q | Url |
| 2025-03-27 | 0001746466 | EQ | 10-K | Url |
| 2024-11-13 | 0001746466 | EQ | 10-Q | Url |
| 2024-08-08 | 0001746466 | EQ | 10-Q | Url |
| 2024-05-09 | 0001746466 | EQ | 10-Q | Url |
| 2024-03-25 | 0001746466 | EQ | 10-K | Url |
| 2023-11-08 | 0001746466 | EQ | 10-Q | Url |
| 2023-08-09 | 0001746466 | EQ | 10-Q | Url |
| 2023-05-11 | 0001746466 | EQ | 10-Q | Url |
| 2023-03-23 | 0001746466 | EQ | 10-K | Url |
| 2022-11-14 | 0001746466 | EQ | 10-Q | Url |
| 2022-08-15 | 0001746466 | EQ | 10-Q | Url |
| 2022-05-12 | 0001746466 | EQ | 10-Q | Url |
| 2022-03-23 | 0001746466 | EQ | 10-K | Url |
| 2021-11-10 | 0001746466 | EQ | 10-Q | Url |
| 2021-08-10 | 0001746466 | EQ | 10-Q | Url |
| 2021-05-13 | 0001746466 | EQ | 10-Q | Url |
| 2021-03-24 | 0001746466 | EQ | 10-K | Url |
| 2020-11-10 | 0001746466 | EQ | 10-Q | Url |
| 2020-08-12 | 0001746466 | EQ | 10-Q | Url |
| 2020-05-13 | 0001746466 | EQ | 10-Q | Url |
| 2020-03-30 | 0001746466 | EQ | S-1 | Url |
| 2020-03-26 | 0001746466 | EQ | 10-K | Url |
| 2019-11-12 | 0001746466 | EQ | 10-Q | Url |
| 2019-08-12 | 0001746466 | EQ | 10-Q | Url |
| 2019-05-13 | 0001746466 | EQ | 10-Q | Url |
| 2019-03-27 | 0001746466 | EQ | 10-K | Url |
| 2018-11-15 | 0001746466 | EQ | 10-Q | Url |
| 2018-09-17 | 0001746466 | EQ | S-1 | Url |
Equillium, Inc(NASDAQ:EQ) 
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune ...
Website: http://www.equilliumbio.com
Founded: 2017
Full Time Employees: 26
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about EQ stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.